Research graph
References from Indications du chimérisme sur cellules triées après allogreffe de cellules souches hématopoïétiques (SFGM-TC). Local targets link to admitted publications; unresolved targets remain external evidence.
New methods for the quantification of mixed chimerism in transplantation
10.3389/fimmu.2023.1023116 · 2023 · External reference
Chimerism analysis for clinicians: a review of the literature and worldwide practices
10.1038/s41409-022-01579-9 · 2022 · External reference
Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction
10.1182/blood.v99.12.4618 · 2002 · External reference
Detection and quantification of chimerism by droplet digital PCR
10.4161/chim.25400 · 2013 · External reference
Digital PCR to assess hematopoietic chimerism after allogeneic stem cell transplantation
10.1016/j.exphem.2015.02.006 · 2015 · External reference
A technical application of quantitative next generation sequencing for chimerism evaluation
10.3892/mmr.2016.5593 · 2016 · External reference
Third-generation nanopore sequencing for post-transplant chimerism monitoring
10.1111/tan.70770 · 2026 · External reference
Chimerism testing in myeloid malignancies: techniques, considerations, and connections to post-transplant outcomes
2025 · External reference
Étude du chimérisme après allogreffe de cellules hématopoïétiques: recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)
10.1016/j.bulcan.2017.08.010 · 2017 · External reference
Unresolved reference
2025 · External reference
A practical guide to chimerism analysis: review of the literature and testing practices worldwide
10.1016/j.humimm.2021.07.013 · 2021 · External reference
Prospects and potential for chimerism analysis after allogeneic hematopoietic stem cell transplantation
10.3390/cells13110993 · 2024 · External reference
Use of chimerism analysis after allogeneic stem cell transplantation: Belgian guidelines and review of the current literature
10.1080/17843286.2020.1754635 · 2021 · External reference
Analysis of subset chimerism for MRD-Detection and pre-emptive treatment in AML
10.3389/fonc.2022.841608 · 2022 · External reference
Ateliers d’harmonisation des pratiques de la SFGM-TC
10.1016/j.bulcan.2016.09.006 · 2016 · External reference
Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome
10.1016/j.leukres.2014.02.001 · 2014 · External reference
Quantitative chimerism in CD3-negative mononuclear cells predicts prognosis in acute myeloid leukemia patients after hematopoietic stem cell transplantation
10.1038/s41375-019-0624-4 · 2020 · External reference
Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia
10.1200/jco.20.02308 · 2021 · External reference
10.1200/jco.2015.62.7273
10.1200/jco.2015.62.7273 · 2015 · External reference
Mixed T cell CHIMERISM in bone marrow at day+30 after allogeneic stem cell transplantation: Correlation with acute GVHD grades III-IV and no impact on relapse and overall survival
10.1111/ejh.13772 · 2022 · External reference
Mixed T lymphocyte chimerism after allogeneic hematopoietic transplantation is predictive for relapse of acute myeloid leukemia and myelodysplastic syndromes
10.1016/j.bbmt.2015.07.005 · 2015 · External reference
Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS
10.1182/bloodadvances.2022009493 · 2023 · External reference
Does early chimerism testing predict outcomes after allogeneic hematopoietic stem cell transplantation?
10.1080/10428194.2020.1827249 · 2021 · External reference
Prognostic limitations of donor T cell chimerism after myeloablative allogeneic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndromes
10.1016/j.bbmt.2017.01.086 · 2017 · External reference
Impact of T-cell chimerism on relapse after cord blood transplantation for hematological malignancies: Nagoya Blood and Marrow Transplantation Group study
10.1038/bmt.2016.323 · 2017 · External reference
Monitoring of WT1 expression in PB and CD34+ donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning
10.1038/leu.2010.283 · 2011 · External reference
CD34(+) lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT
10.1038/bmt.2013.2 · 2013 · External reference
Monitoring of acute myeloid leukemia patients after allogeneic stem cell transplantation employing semi-automated CD34+ donor cell chimerism analysis
10.1007/s00277-013-1961-4 · 2014 · External reference
CD34+ chimerism analysis for minimal residual disease monitoring after allogeneic hematopoietic cell transplantation
10.1016/j.leukres.2018.10.007 · 2018 · External reference
Impact on outcomes of mixed chimerism of bone marrow CD34+ sorted cells after matched or haploidentical allogeneic stem cell transplantation for myeloid malignancies
10.1038/s41409-022-01747-x · 2022 · External reference
Risk assessment of relapse by lineage-specific monitoring of chimerism in children undergoing allogeneic stem cell transplantation for acute lymphoblastic leukemia
10.3324/haematol.2015.135137 · 2016 · External reference
Peripheral blood CD34 donor chimerism has greater clinical utility than CD3 for detecting relapse after allogeneic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndrome
10.1016/j.jtct.2023.03.025 · 2023 · External reference
Lineage-specific early complete donor chimerism and risk of relapse after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia
10.1038/s41409-022-01615-8 · 2022 · External reference
Early relapse prediction after allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia (ALL) using lineage-specific chimerism analysis
10.1002/jha2.568 · 2022 · External reference
Comparison of chimerism kinetics and associated outcomes in patients receiving post-transplant cyclophosphamide versus methotrexate based GVHD prophylaxis following allogeneic hematopoietic cell transplant
10.1016/j.jtct.2025.05.006 · 2025 · External reference
Early mixed lymphoid donor/host chimerism is associated with improved transplant outcome in patients with primary or secondary myelofibrosis
10.1016/j.bbmt.2020.07.013 · 2020 · External reference
Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation
10.3324/haematol.2019.223503 · 2019 · External reference
Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis
10.1038/s41408-020-0302-9 · 2020 · External reference
Donor-host lineage-specific chimerism monitoring and analysis in pediatric patients following allogeneic stem cell transplantation: influence of pre-transplantation variables and correlation with post-transplant outcomes
10.1016/j.jtct.2021.05.020 · 2021 · External reference
Injections de lymphocytes du donneur (DLI): recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)
10.1016/j.bulcan.2018.10.002 · 2019 · External reference
Outcomes after donor lymphocyte infusion in patients with hematological malignancies: donor characteristics matter
10.1016/j.jtct.2022.01.022 · 2022 · External reference
Full donor chimerism without graft-versus-host disease: the key factor for maximum benefit of pre-emptive donor lymphocyte infusions (pDLI)
10.1038/s41409-019-0695-x · 2020 · External reference
10.1016/j.clml.2024.07.006
10.1016/j.clml.2024.07.006 · 2024 · External reference
Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning
10.1016/j.bbmt.2014.07.003 · 2014 · External reference
Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival
10.1016/j.bbmt.2014.05.025 · 2014 · External reference
Very early lineage-specific chimerism after reduced intensity stem cell transplantation is highly predictive of clinical outcome for patients with myeloid disease
10.1016/j.leukres.2019.106173 · 2019 · External reference
Utility of assessing CD3+ cell chimerism within the first months after allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia
10.1111/tan.14557 · 2022 · External reference
The predictive value of T-cell chimerism for disease relapse after allogeneic hematopoietic stem cell transplantation
10.3389/fimmu.2024.1382099 · 2024 · External reference
Early mixed donor chimerism is a strong negative prognostic indicator in allogeneic stem cell transplant for AML and MDS
10.1016/j.jtct.2024.11.006 · 2025 · External reference
10.1111/j.1365-2141.2008.07533.x
10.1111/j.1365-2141.2008.07533.x · 2009 · External reference
The incidence, clinical outcome, and protective factors of mixed chimerism following hematopoietic stem cell transplantation for severe aplastic anemia
10.1111/ctr.14160 · 2021 · External reference
Mixed T cell chimerism after allogeneic hematopoietic stem cell transplantation for severe aplastic anemia using an alemtuzumab-containing regimen is shaped by persistence of recipient CD8T cells
10.1016/j.bbmt.2016.11.003 · 2017 · External reference
Does mixed chimerism after allogeneic hematopoietic cell transplantation in pediatric patients with fanconi anemia impact on outcome?
10.1016/j.jtct.2020.11.024 · 2021 · External reference
Donor T-cell and myeloid chimerism is higher after cord blood transplant than with other cell sources
10.1016/j.jcyt.2025.07.003 · 2025 · External reference
Relationship between mixed donor-recipient chimerism and disease recurrence after hematopoietic cell transplantation for sickle cell disease
10.1016/j.bbmt.2017.08.038 · 2017 · External reference
Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype
10.1001/jama.2014.7192 · 2014 · External reference
Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies
10.1002/ajh.24183 · 2015 · External reference
Relationship between mixed chimerism and rejection after bone marrow transplantation in thalassaemia
2008 · External reference
Long-term event-free survival, chimerism and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched-sibling transplantation in France
10.3324/haematol.2018.213207 · 2020 · External reference
Transfusion support for patients with sickle cell disease
10.1016/j.transci.2022.103556 · 2022 · External reference
Extensive multilineage analysis in patients with mixed chimerism after allogeneic transplantation for sickle cell disease: insight into hematopoiesis and engraftment thresholds for gene therapy
10.3324/haematol.2019.227561 · 2020 · External reference
Donor chimerism and immune reconstitution following haploidentical transplantation in sickle cell disease
10.3389/fimmu.2022.1055497 · 2022 · External reference
Assessment of donor cell engraftment after hematopoietic stem cell transplantation for sickle cell disease: a review of current and future methods
10.1002/ajh.26599 · 2022 · External reference
SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery
10.1182/blood-2018-03-840702 · 2018 · External reference
Effect of stem cell source on long-term chimerism and event-free survival in children with primary immunodeficiency disorders after fludarabine and melphalan conditioning regimen
10.1016/j.jaci.2016.01.053 · 2016 · External reference
The significance of mixed chimaerism and cell lineage chimaerism monitoring in paediatric patients post haematopoietic stem cell transplant
10.1111/bjh.18190 · 2022 · External reference
Isolated full donor T-Cell chimerism after haploidentical TCRαβ/CD19 depleted HSCT maintains remission of familial HLH
10.1007/s10875-023-01612-6 · 2023 · External reference
Hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report
10.1182/bloodadvances.2025017662 · 2026 · External reference
Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation
10.1182/blood-2007-03-076679 · 2008 · External reference
Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study
10.1182/blood-2010-11-319376 · 2011 · External reference
Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report
10.1182/blood.2019002939 · 2020 · External reference
Outcomes following hematopoietic cell transplantation for Wiskott–Aldrich syndrome
10.1038/bmt.2012.31 · 2012 · External reference
Viral infections in HSCT: detection, monitoring, clinical management, and immunologic implications
10.3389/fimmu.2020.569381 · 2021 · External reference
